(News Bulletin 247) – Stifel maintains its buy rating on Bayer shares, with an unchanged price target of 68 euros.
The analyst returns to the conference call of the general manager analyzing the various strategic options regarding the structure of the company.
“The task is to decide whether the current structure is the best to accomplish the mission of all segments,” says Stifel.
While the head of the Consumer Health division highlighted the advantages of being part of Bayer, the head of the Pharma division mentioned the limitation of capital allocations, and that Crop Science had difficulties in terms of speed of implementation. the market.
“We see these comments as signs that a spin-off of the company could be on the agenda,” said Stifel, who believes that this transaction could “unlock value for shareholders”.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
